Global Atherectomy Devices Market Grows Steadily at a CAGR of 6.7%

Introduction

Atherectomy devices are crucial in treating peripheral artery disease (PAD) and coronary artery disease (CAD) by removing or reshaping arterial plaque, which obstructs blood flow. These devices use various methods such as rotational, directional, or laser-assisted techniques to effectively break down plaque without causing significant damage to the surrounding blood vessels. The goal is to restore proper circulation, improve oxygen delivery to tissues, and reduce symptoms like pain and fatigue.

Market Dynamics

Rising incidence of cardiovascular diseases drives the global market

The growing incidence of cardiovascular diseases (CVDs), particularly peripheral artery disease (PAD) and coronary artery disease (CAD), is a key driver of the atherectomy devices market. Lifestyle factors such as physical inactivity, poor dietary habits, smoking, and the increasing prevalence of diabetes are contributing to a larger population in need of arterial plaque removal procedures.

• For instance, in June 2023, the American Heart Association (AHA) highlighted a sharp rise in PAD cases, estimating that more than 200 million people worldwide are affected. This increase emphasizes the growing demand for advanced atherectomy solutions to effectively treat arterial blockages.

As the global burden of cardiovascular diseases continues to escalate, the need for innovative atherectomy devices is projected to rise significantly.

Innovations in next-gen atherectomy devices create tremendous opportunities

The development of next-generation atherectomy devices offers a substantial opportunity in the market. These cutting-edge devices integrate AI-powered navigation, real-time imaging, and bioabsorbable materials, boosting precision, safety, and long-term effectiveness. New innovations, such as laser-assisted and hybrid atherectomy systems, are broadening treatment options for complex arterial lesions.

• For example, a March 2024 study published in the National Library of Medicine spotlighted a multifunctional atherectomy device designed for iliac and popliteal artery occlusions in patients with peripheral artery occlusive disease (PAOD). This device combines atherectomy, thrombectomy, and transit functions, reducing treatment costs. The study reported positive outcomes and recommended further multicenter trials for validation.

Regional Analysis

North America holds the dominant position in the global atherectomy devices market, driven by the high prevalence of peripheral artery disease and the strong adoption of advanced vascular interventions. The region benefits from substantial R&D investments, a well-established healthcare infrastructure, and favorable reimbursement policies that encourage the use of atherectomy procedures. Moreover, the presence of key market players and continuous technological advancements, such as AI-integrated atherectomy systems and robotic-assisted interventions, further accelerate market growth.

Key Highlights

• The global atherectomy devices market size was valued at USD 1,054.6 million in 2024 and is projected to grow from USD 1,153.6 million in 2025 to reach USD 1,945.0 million by 2033, exhibiting a CAGR of 6.7% during the forecast period (2025-2033).
• Based on type, the global market is segmented into excisional atherectomy, laser ablation atherectomy, orbital atherectomy, and rotational atherectomy. The rotational atherectomy segment is the largest revenue contributor to the market.
• Based on application, the global market is segmented into coronary artery disease, peripheral arterial disease, and others. The peripheral arterial disease segment is the largest revenue contributor to the market.
• Based on end-users, the global atherectomy devices market is segmented into hospitals, ambulatory surgery centers, and others. The hospital segment is the largest revenue contributor to the market.
• North America is the highest shareholder in the global market.

Competitive Players

1. AngioDynamics
2. Abbott Laboratories
3. B.Braun SE
4. Biomerics LLC
5. Boston Scientific Corporation
6. Becton
7. Dickinson and Company
8. Cardinal Health Inc.
9. Cardiovascular Systems Inc.
10. Koninklijke Philips NV
11. Medtronic
12. RA Medical
13. Terumo Corporation
14. Straub Medical

Recent Developments

• In April 2024, Otsuka Medical Devices Co., Ltd. announced a definitive agreement to transfer the distribution of the Diamondback 360 Coronary Orbital Atherectomy System (OAS) in Japan to Abbott Medical Japan LLC. This strategic move is expected to expand the market reach of the Diamondback 360 system in Japan, leveraging Abbott's established distribution network and expertise in cardiovascular interventions.

Segmentation

1. By Type
   1. Excisional Atherectomy
   2. Laser Ablation Atherectomy
   3. Orbital Atherectomy
   4. Rotational Atherectomy
2. By Applications&nbsp
   1. Coronary Artery Disease
   2. Peripheral Arterial Disease
   3. Others
3. By End-User&nbsp
   1. Hospitals
   2. Ambulatory Surgery Centers
   3. Others
4. By Regions
   1. North America
   2. Europe
   3. Asia-Pacific
   4. Central & South America
   5. The Middle East and Africa